Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarillo Biosciences has filed a patent application with the US Patent and Trademark Office with claims to methods of treating chronic cough by administering interferon orally to diminish cough duration, frequency and intensity.
Subscribe to our email newsletter
A study to confirm the efficacy of oral interferon in the treatment of chronic cough will be launched in January at a major Texas university. This Phase II, double-blind, placebo-controlled trial of 40 chronic obstructive pulmonary disease patients is expected to be completed in mid 2008.
Joseph Cummins, president and CEO of Amarillo Biosciences, said: “Because of the size of the chronic cough market, this is the most important patent application that the company has ever submitted to the US Patent Office.”